The effect of semaglutide in subjects with non-cirrhotic non-alcoholic steatohepatitis
Latest Information Update: 17 Jul 2024
At a glance
- Drugs Semaglutide (Primary)
- Indications Hepatic fibrosis; Non-alcoholic steatohepatitis
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms ESSENCE
- Sponsors Novo Nordisk
- 28 May 2024 Planned primary completion date changed from 7 Mar 2029 to 25 Apr 2029.
- 28 Feb 2024 Planned End Date changed from 20 Jul 2029 to 25 Apr 2029.
- 28 Feb 2024 Planned primary completion date changed from 7 Apr 2028 to 7 Mar 2029.